Genetic testing has revolutionized diagnosis of rare diseases, enabling identification of underlying molecular defects that guide treatment selection and family counseling. Advances in sequencing technology have made comprehensive genetic testing increasingly accessible. For comprehensive analysis of this trend, refer to the Orphan Drugs Market report.

Next-generation sequencing enables simultaneous analysis of multiple genes, whole exomes, or whole genomes, dramatically improving diagnostic yield for rare diseases. Patients who have undergone years of diagnostic odyssey can now receive answers through comprehensive testing. Earlier diagnosis enables earlier intervention and improved outcomes.

Newborn screening programs increasingly incorporate genetic testing for treatable rare diseases, enabling presymptomatic diagnosis and prompt treatment initiation. Early intervention can prevent irreversible damage and improve long-term outcomes. Expansion of newborn screening panels continues as new treatments become available.

Genetic test results guide selection of targeted therapies for patients with specific molecular alterations. In oncology, tumor genomic profiling identifies patients who may benefit from matched targeted therapies. In genetic disorders, molecular diagnosis enables enrollment in gene therapy trials and other precision medicine approaches.

The growth of genetic testing reflects recognition that molecular diagnosis is essential for optimal management of rare diseases. As testing becomes more accessible and comprehensive, its role in orphan drug development and clinical care will likely expand.